新桥生物(NBP)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NBP 新桥生物

盘前交易 07-06 04:42:45 EDT

2.14

+0.15

+7.54%

盘前2.20

+0.06+2.80%

04:02 EDT

最高2.27	最低2.01	成交量155.87万
今开2.01	昨收1.99	日振幅13.05%
总市值2.47亿	流通市值1.38亿	总股本1.15亿
成交额338.41万	换手率2.42%	流通股本6,448万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NBP","market":"US","secType":"STK","nameCN":"新桥生物","latestPrice":2.14,"timestamp":1783022400000,"preClose":1.99,"halted":0,"volume":1558747,"hourTrading":{"tag":"盘前","latestPrice":2.2,"preClose":2.14,"latestTime":"04:02 EDT","volume":700,"amount":1540.0000000000002,"timestamp":1783324947296,"change":0.06,"changeRate":0.028037,"amplitude":0},"delay":0,"changeRate":0.07537688442211062,"floatShares":64483700,"shares":115266053,"eps":-0.483,"marketStatus":"盘前交易","change":0.15,"latestTime":"07-06 04:42:45 EDT","open":2.01,"high":2.2697,"low":2.01,"amount":3384062.0270821,"amplitude":0.130503,"askPrice":2.47,"askSize":100,"bidPrice":2.14,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.483,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783344600000},"marketStatusCode":1,"adr":0,"adrRate":2.3,"listingDate":1579237200000,"exchange":"NASDAQ","adjPreClose":2.14,"preHourTrading":{"tag":"盘前","latestPrice":2.2,"preClose":2.14,"latestTime":"04:02 EDT","volume":700,"amount":1540.0000000000002,"timestamp":1783324947296,"change":0.06,"changeRate":0.028037,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":2.2,"preClose":2.14,"latestTime":"19:54 EDT","volume":8507,"amount":18620.462,"timestamp":1783036494384,"change":0.06,"changeRate":0.028037,"amplitude":0.055187},"volumeRatio":1.2147266850241285,"impliedVol":0.5688,"impliedVolPercentile":0.2083},"requestUrl":"/m/hq/s/NBP","defaultTab":"news","newsList":[{"id":"1199400680","title":"新桥生物旗下Givastomig的注册性三期临床试验最早有望于2026年第四季度启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1199400680","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199400680?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:01","pubTimestamp":1781607678,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）宣布，其核心候选药物Givastomig的注册性三期临床试验，预计最早将于2026年第四季度开始。这一关键性试验的启动，标志着该药物在特定适应症研发进程中迈入决定性阶段，为后续的监管申报和潜在商业化铺平道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148595922","title":"新桥生物Givastomig获FDA快速通道资格，用于一线治疗HER2阴性转移性胃癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1148595922","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148595922?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:00","pubTimestamp":1781607647,"startTime":"0","endTime":"0","summary":"新桥生物宣布，其研发的Givastomig已获得美国食品药品监督管理局（FDA）授予的快速通道资格，该资格针对的适应症为一线治疗HER2阴性转移性胃癌。此项认定有望加速该药物的研发与审评进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120501405","title":"新桥生物：FDA确认Givastomig有望符合加速审批资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1120501405","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120501405?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:39","pubTimestamp":1773664740,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式确认，新桥生物（NovaBridge Biosciences）旗下在研药物Givastomig具备潜在资格，有望通过加速审批通道推进上市进程。\n这一进展意味着，若后续临床试验数据积极，Givastomig或可基于替代终点提前获批，从而缩短其进入市场的时间。加速审批路径通常适用于针对严重疾病、且现有治疗选择有限的创新疗法。\n新桥生物表示，将继续与FDA保持密切沟通，积极推进Givastomig的临床开发计划，以期早日为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139570168","title":"新桥生物计划于2026年第四季度启动以客观缓解率为主要终点的注册性三期联合试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1139570168","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139570168?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:03","pubTimestamp":1773658990,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）宣布，公司将于2026年第四季度正式启动一项注册性三期联合疗法临床试验。该试验将采用客观缓解率（ORR）作为主要疗效终点，旨在评估创新疗法组合在目标患者群体中的治疗效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106527073","title":"新桥生物宣布与FDA就胃腺癌药物Givastomig加速审批路径达成建设性B类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1106527073","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106527073?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:02","pubTimestamp":1773658924,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）近日披露，该公司与美国食品药品监督管理局（FDA）针对其在研药物Givastomig用于治疗胃腺癌的加速批准路径，成功举行了一场富有成效的B类会议。\n此次会议重点探讨了Givastomig通过加速审批通道上市的可能性，双方就后续临床开发策略及数据要求达成重要共识。该进展标志着Givastomig在胃腺癌治疗领域的商业化进程迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184660068","title":"新桥生物公布二期a阶段顶线数据：Vis-101为湿性年龄相关性黄斑变性提供快速、强劲且持久的治疗反应","url":"https://stock-news.laohu8.com/highlight/detail?id=1184660068","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184660068?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:02","pubTimestamp":1773054152,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）最新发布的二期a阶段临床试验顶线数据显示，其核心候选药物Vis-101在治疗湿性年龄相关性黄斑变性（wet AMD）方面展现出卓越疗效。研究结果表明，该疗法能诱导快速起效、强劲且持久的治疗反应，为患者提供了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179612326","title":"新桥生物Vis-101试验结果亮眼：平均BCVA改善超10个ETDRS字母，中位CST降低100-150微米","url":"https://stock-news.laohu8.com/highlight/detail?id=1179612326","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179612326?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:02","pubTimestamp":1773054140,"startTime":"0","endTime":"0","summary":"新桥生物近日公布了其候选药物Vis-101的临床试验数据，结果显示其在治疗相关眼部疾病方面取得了显著成效。\n数据显示，接受Vis-101治疗的患者群体，其最佳矫正视力出现了具有临床意义的提升，平均改善幅度超过了10个ETDRS字母。与此同时，患者的中位中心凹厚度也呈现出显著下降，降低范围在100至150微米之间。\n这些积极的数据指标，为Vis-101后续的临床开发路径提供了有力的支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132480297","title":"新桥生物任命生物技术领袖埃米特·T·坎宁安博士为董事会副主席，加速全球生物技术平台发展","url":"https://stock-news.laohu8.com/highlight/detail?id=1132480297","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132480297?lang=zh_cn&edition=full","pubTime":"2026-02-19 20:02","pubTimestamp":1771502522,"startTime":"0","endTime":"0","summary":"新桥生物宣布任命生物技术领域的杰出领导者埃米特·T·坎宁安博士为董事会副主席。这一重要人事任命旨在进一步加速公司全球生物技术平台的拓展与创新。坎宁安博士在医学、科研及公共卫生领域拥有深厚的学术背景和丰富的行业经验，他的加入将为新桥生物的战略发展注入强劲动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106070252","title":"新桥生物全球首例患者入组：Givastomig联合免疫化疗治疗一线转移性胃癌的随机二期研究启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1106070252","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106070252?lang=zh_cn&edition=full","pubTime":"2026-02-18 05:07","pubTimestamp":1771362463,"startTime":"0","endTime":"0","summary":"新桥生物宣布，其全球性、随机二期临床研究已完成首例患者给药。该研究旨在评估Givastomig与免疫化疗联合方案，用于一线治疗转移性胃癌患者的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610254671","title":"新桥生物盘中异动 早盘急速下挫5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610254671","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610254671?lang=zh_cn&edition=full","pubTime":"2026-02-10 22:46","pubTimestamp":1770734803,"startTime":"0","endTime":"0","summary":"北京时间2026年02月10日22时46分，新桥生物股票出现波动，股价快速跳水5.19%。截至发稿，该股报3.29美元/股，成交量6.1783万股，换手率0.05%，振幅6.14%。新桥生物股票所在的生物技术行业中，整体涨幅为0.10%。其相关个股中，Quince Therapeutics, Inc.、Abpro Holdings, Inc、Evommune, Inc.涨幅较大，Abpro Holdings, Inc、Phio Pharmaceuticals Corp.、Quince Therapeutics, Inc.较为活跃，换手率分别为1388.98%、724.16%、639.30%，振幅较大的相关个股有Quince Therapeutics, Inc.、Abpro Holdings, Inc、Lunai Bioworks Inc.，振幅分别为58.92%、31.58%、22.91%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210224643a49411ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210224643a49411ad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609188205","title":"华尔街顶级分析师最新评级：亚马逊遭下调，罗布乐思获上调","url":"https://stock-news.laohu8.com/highlight/detail?id=2609188205","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609188205?lang=zh_cn&edition=full","pubTime":"2026-02-07 00:42","pubTimestamp":1770396120,"startTime":"0","endTime":"0","summary":"华尔街最受关注、对市场影响显著的分析师研报评级调仓信息汇总如下。罗布乐思：自由资本将其评级从持有上调至买入，目标价维持 85 美元不变。受股价较 52 周高点回落 25% 影响，当前估值具备优势，成为机构上调评级的核心原因。因公司当前股价已高于机构目标价，估值偏高成为此次评级下调的主因。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-07/doc-inhkxcfv7836258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0079474960.USD","LU1974910355.USD","LU1119994496.HKD","LU0320765059.SGD","LU0175139822.USD","LU1244550221.USD","LU1551013425.SGD","LU0642271901.SGD","LU2265009873.SGD","ROKU","LU2764262908.HKD","LU0640476718.USD","IE00B1BXHZ80.USD","LU1989764664.SGD","LU2211815571.USD","LU2247934214.USD","LU0980610538.SGD","LU1496350171.SGD","IE0002270589.USD","IE0034235303.USD","IE00B4YYXB79.USD","LU2750360641.GBP","RBLX","IE00BZ1G4Q59.USD","LU2108987350.USD","LU0672654240.SGD","IE00B7SZLL34.SGD","LU0109391861.USD","IE00B1XK9C88.USD","LU0061474960.USD","BK4507","LU1496350502.SGD","LU1861559042.SGD","LU1035775433.USD","LU2213496289.HKD","LU1316542783.SGD","IE00B19Z9505.USD","LU0724617625.USD","LU2083900584.USD","SG9999018857.SGD","LU0158827948.USD","BK4532","LU0310799852.SGD","LU0082616367.USD","LU0128525929.USD","LU1720051108.HKD","SG9999000418.SGD","LU0308772762.SGD","LU1066051498.USD","BK4598","IE0009G5SDU7.USD","LU0345768740.USD","LU0345769128.USD","LU0683600562.USD","LU2125154935.USD","LU1868836914.USD","BK4596","LU0648001328.SGD","LU0985320562.USD","JMIA","LU1069344957.HKD","SGXZ51526630.SGD","LU0302445910.USD","LU0494093205.USD","LU0256863902.USD","LU2381873111.SGD","LU0208291251.USD","LU2065170008.USD","LU1066051225.USD","LU2764263039.SGD","LU0965509010.AUD","LU2168564065.EUR","LU2168564149.EUR","IE00BYQQ9H92.USD","LU1914381329.SGD","LU2756315664.SGD","IE00B19Z8W00.USD","LU0056508442.USD","LU0061474705.USD","LU2065169927.USD","LU2023250504.SGD","LU2111349929.HKD","BK4122","BK4585","IE00BN29S564.USD","LU1917777945.USD","SG9999002232.USD","LU2896262040.SGD","LU2543165471.USD","LU0345768153.USD","LU0456855351.SGD","LU1064131342.USD","LU1116320901.HKD","LU0289941410.SGD","LU2471134879.HKD","LU1074936037.SGD","LU0011850046.USD","LU0345770308.USD","LU2505996509.AUD","LU2357305700.SGD","LU1868837300.USD","BK4561","LU0788109477.HKD","LU2089284900.SGD","LU2487616109.SGD","LU0210536198.USD","LU1116320737.USD","IE00B19Z3B42.SGD","LU2592432038.USD","IE00BJTD4V19.USD","BK4588","LU2028103732.USD","LU1267930730.SGD","LU1839511570.USD","LU2463028550.USD","SIRI","LU1935043023.USD","LU0648000940.SGD","LU2430703251.USD","LU0210528500.USD","LU2471134523.USD","LU2746668461.USD","LU0072462426.USD","LU0077335932.USD","SG9999015986.USD","LU2077746001.SGD","LU1935042488.USD","BK4527","LU0072461881.USD","IE000ITXATA3.USD","LU1548497426.USD","LU0466842654.USD","BK4565","BK4220","SG9999001077.SGD","LU0109392836.USD","LU2552382215.SGD","LU1720051017.SGD","SG9999014898.SGD","LU1066053197.SGD","LU1366192091.USD","LU0708995401.HKD","LU1791710582.SGD","BK4551","PI","IE0004086264.USD","LU1066051811.HKD","LU0154236417.USD","LU0070217475.USD","LU2237438978.USD","LU2063271972.USD","LU0965509101.SGD","LU2361044865.SGD","LU2317271919.USD","SG9999015952.SGD","LU0965509283.SGD","LU0080751232.USD","LU0157215616.USD","LU2720916845.USD","HK0000914660.USD","LU0211328371.USD","LU0312595415.SGD","LU1934455863.HKD","SG9999014880.SGD","IE00BFSS7M15.SGD","LU2360032135.SGD","SGXZ81514606.USD","LU0097036916.USD","LU1244550577.SGD","LU2361044949.HKD","LU0251132253.USD","LU0345769631.USD","LU1778281490.HKD","IE0004091025.USD","IE00BQXX3D17.EUR","LU0345774631.USD","LU1814569148.SGD","LU2430703095.HKD","IE00BWXC8680.SGD","IE00BKVL7J92.USD","LU1145028129.USD","LU1127390331.HKD","IE00BKPKM429.USD","LU1674673428.USD","LU2471134952.CNY","LU2237957902.USD","LU0162691827.USD","LU0149725797.USD","LU1803068979.SGD","LU1934455277.USD","LU0234572021.USD","IE00BJLML261.HKD","LU1718418525.SGD","SG9999014906.USD","SGXZ23171101.USD","BK4550","LU1935043536.SGD","BK4524","LU1674673691.USD","LU1551013342.USD","BK4533","IE0003U64NQ7.SGD","LU2106854487.HKD","LU2168563687.JPY","LU2462157665.USD","LU0820561818.USD","LU0353189763.USD","SGXZ31699556.SGD","LU2089283258.USD","SGXZ99366536.SGD","SG9999015978.USD","LU1084165304.USD","SG9999018865.SGD","BK4538","LU1633808545.USD","LU0029864427.USD","LU1435385759.SGD","LU1244550494.USD","IE00BMPRXR70.SGD","LU0353189680.USD","LU0234570918.USD","LU1037948897.HKD","AMZD","LU0823434740.USD","BK4604","LU0957791311.USD","AMZW","LU2505996681.GBP","LU0823411888.USD","AMZN","LU1235294995.USD","IE000W1ABFV2.USD","LU2125154778.USD","LU0310800379.SGD","LU0882574139.USD","IE00BKDWB100.SGD","LU0170899867.USD","AMZY","LU2756315318.SGD","IE00BJJMRY28.SGD","SRE","SG9999014914.USD","LU0096362180.USD","LU2362541513.USD","LU0061475181.USD","LU1934455194.USD","LU1791710400.SGD","BK4547","LU1815333072.USD","LU2417539215.USD","LU2326559502.SGD","IE00BK4W5L77.USD","LU1880398471.USD","IE0001KFT4U8.USD","BK4543","LU2264538146.SGD","LU0048584097.USD","LU2054465674.USD","MMSI","LU2168564495.EUR","LU1883839398.USD","LU1935042215.USD","JBS","NBP","LU2211817866.USD","LU1037948541.HKD","BK4581","LU2430703178.SGD","LU0130103400.USD","BK4535","LU2360106780.USD","LU0127658192.USD","IE00BFSS8Q28.SGD","IE000YTNTUN2.SGD","LU0787776722.HKD","AMZU","LU0256863811.USD","LU1988902786.USD","SG9999004303.SGD","LU2092627202.USD","LU1232071149.USD","LU1868837136.USD","LU2237957811.SGD","LU0276348264.USD","EL","LU0267386448.USD","HK0000914686.HKD","IE00BMPRXQ63.HKD","LU0354030438.USD","LU2764263203.CNY","LU2087625088.SGD","LU1280957306.USD","LU1267930573.SGD","LU0053666078.USD","LU2275660780.HKD","LU0323591593.USD","LU0203202063.USD","BK4612","LU0210533765.USD","LU2065171311.SGD","IE000KEQY171.SGD","LU2361045086.USD","LU2860962120.EUR","LU2461242641.AUD","LU0823421416.USD","GB00BDT5M118.USD","BK4592","LU1861558580.USD","LU2023251221.USD","LU0820561909.HKD","LU2242650005.HKD","IE00BK4W5M84.HKD","LU2602419157.SGD","LU0070302665.USD","LU1989764748.USD","BK4503","LU0943347566.SGD","USAW.SI","IE00B3SWFQ91.USD","LU0158827781.USD","LU1691799644.USD","LU2087621335.USD","IE00BJTD4N35.SGD","LU1804176565.USD","IE00BJJMRX11.SGD","LU2552382132.HKD","LU0708994859.HKD","SG9999017495.SGD","LU2097829019.USD","IE00B19Z8X17.USD","LU1629891620.HKD","LU1861127337.USD","IE00B5TLWC47.USD","LU1823568750.SGD","LU1935042991.SGD","LU0354030511.USD","LU2420271590.USD","LU2023250330.USD","LU2242649171.HKD","LU0345770993.USD","BOOT","LU1868836591.USD","LU2552382058.USD","LU1046421795.USD","IE0004445239.USD","IE00BQXX3C00.GBP","LIN","LU0417517546.SGD","LU0786609619.USD","IE00BFXG0V08.USD","LU0198837287.USD","LU1201861165.SGD","BK4579","LU0320765489.SGD","LU0215105999.USD","LU0965508806.USD","LU1366333091.USD","IE00B19Z3581.USD","LU0820562030.AUD","LU0265550946.USD","IE00B4JS1V06.HKD","BK4548","IE0004445015.USD","LU0203201768.USD","BK4566","LU0345774391.USD","LU0289960550.SGD","LU0238689110.USD","LU2236285917.USD","BK4534","BK4554","LU0823421333.USD","LU2456880835.USD","LU0107464264.USD","LU1852331112.SGD","LU0342679015.USD","LU1429558221.USD","LU1267930490.SGD","LU1201861249.SGD","IE00BMPRXN33.USD","LU0348723411.USD","LU0390134368.USD","LU0316494557.USD","LU0719512351.SGD","BK4085","LU2746668974.SGD","LU2362541273.HKD","IE00B3S45H60.SGD","LU2092937148.SGD","SG9999002224.SGD","LU1868836757.USD","LU2750360997.AUD","LU1153585028.USD","AMZZ","LU0528227936.USD","AZYY","IE00B7KXQ091.USD","SG9999015945.SGD","BK4559","LU2065171402.SGD","LU0823434583.USD","IE00B775SV38.USD","IE00BQXX3F31.USD","LU2471134796.USD","LU0861579265.USD","LU2452424414.USD","LU0211327993.USD","IE0005OL40V9.USD","IE00B5949003.HKD","LU0889565833.HKD","LU2271345857.HKD","LU2403377893.USD","IE00B775H168.HKD","LU2362540622.SGD","LU1880398554.USD","HUBG","LU0265550359.USD","LU1323610961.USD","LU1261432733.SGD","LU0964807845.USD","LU0314104364.USD","LU2168564222.USD","LU2250418816.HKD","LU0689472784.USD","LU0096364046.USD","IE0009356076.USD","SNAP","LU0130102774.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1119906453","title":"新桥生物联合疗法耐受性良好 安全性媲美现行标准治疗方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1119906453","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119906453?lang=zh_cn&edition=full","pubTime":"2026-01-06 20:13","pubTimestamp":1767701586,"startTime":"0","endTime":"0","summary":"新桥生物最新研究数据显示，其开发的联合治疗方案展现出优异的耐受性特征，安全性与当前标准治疗方案相当。该结果表明该疗法在维持疗效的同时，未增加额外安全性风险，为患者提供了更优的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133190087","title":"新桥生物联合疗法安全性特征与既往观察相似，免疫相关性胃炎引发关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1133190087","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133190087?lang=zh_cn&edition=full","pubTime":"2026-01-06 20:04","pubTimestamp":1767701071,"startTime":"0","endTime":"0","summary":"新桥生物最新研究数据显示，其联合疗法的整体安全性特征与早期观察结果基本一致。值得注意的是，研究中出现了免疫相关性胃炎病例，这一发现为后续临床监测提供了重要参考依据。研究人员指出，该不良反应属于已知免疫检查点抑制剂治疗的潜在风险范畴，目前所有病例均通过标准医疗干预得到有效控制。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114840344","title":"新桥生物公布Givastomig联合疗法一线治疗转移性胃癌IB期剂量扩展积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1114840344","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114840344?lang=zh_cn&edition=full","pubTime":"2026-01-06 20:04","pubTimestamp":1767701043,"startTime":"0","endTime":"0","summary":"新桥生物今日公布了其Givastomig联合疗法在IB期临床试验剂量扩展阶段的最新数据，该研究针对一线治疗转移性胃癌患者。\n数据显示，在剂量扩展队列中，Givastomig展现出令人鼓舞的临床活性与可控的安全性特征。这一积极进展为后续临床开发提供了重要依据。\n研究采用阶梯式剂量递增方案，逐步探索Givastomig与标准化疗联合使用的最佳治疗窗口。最新分析结果证实了该疗法在肿瘤缩小率和疾病控制率方面的潜在优势。\n目前，研究团队正进一步分析生物标志物数据，以识别最可能从该疗法中获益的患者群体。这些发现将为即将开展的注册性临床研究奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novabridge.com","stockEarnings":[{"period":"1week","weight":0.3375},{"period":"1month","weight":0.2515},{"period":"3month","weight":-0.1193},{"period":"6month","weight":-0.4988},{"period":"1year","weight":-0.0655},{"period":"ytd","weight":-0.4623}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"新桥生物于2016年6月30日在开曼群岛注册成立。该公司是一家全球生物技术平台，专注于开发创新的免疫肿瘤疗法。其研发管线包括三个临床阶段项目，其中givastomig是一种用于治疗胃癌的CLDN18.2双特异性抗体，是公司的核心产品。通过其子公司Visara，公司还在开发用于视网膜疾病的VIS-101。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.014966},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.04486},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.139701},{"month":4,"riseRate":0.571429,"avgChangeRate":0.057761},{"month":5,"riseRate":0.571429,"avgChangeRate":0.069758},{"month":6,"riseRate":0.857143,"avgChangeRate":0.201798},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.050205},{"month":8,"riseRate":0.333333,"avgChangeRate":0.044996},{"month":9,"riseRate":0.5,"avgChangeRate":-0.071754},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.01521},{"month":11,"riseRate":0.166667,"avgChangeRate":-0.055941},{"month":12,"riseRate":0.666667,"avgChangeRate":0.047406}],"exchange":"NASDAQ","name":"新桥生物","nameEN":"NovaBridge Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"新桥生物(NBP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供新桥生物(NBP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"新桥生物,NBP,新桥生物股票,新桥生物股票老虎,新桥生物股票老虎国际,新桥生物行情,新桥生物股票行情,新桥生物股价,新桥生物股市,新桥生物股票价格,新桥生物股票交易,新桥生物股票购买,新桥生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"新桥生物(NBP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供新桥生物(NBP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}